Corbus Pharmaceuticals Holdings, Inc. (CRBP) Bundle
Understanding Corbus Pharmaceuticals Holdings, Inc. (CRBP) Revenue Streams
Understanding Corbus Pharmaceuticals Holdings, Inc.’s Revenue Streams
Corbus Pharmaceuticals Holdings, Inc. has not generated any revenues from the sale of products as of 2024. The company is focused on developing its product candidates, which are still in the clinical trial phase. Therefore, there are no primary revenue sources to report, including products or services.
Year-over-Year Revenue Growth Rate
As the company has not generated any revenue, there is no year-over-year revenue growth rate to analyze. The focus remains on research and development, with significant financial expenditures directed toward clinical trials and operational costs.
Contribution of Different Business Segments to Overall Revenue
Since there are no revenues, the contribution of different business segments to overall revenue is effectively zero. The company is primarily incurring expenses related to research and development, with no income generated from product sales or services.
Analysis of Significant Changes in Revenue Streams
There have been no changes in revenue streams as the company has not commenced revenue-generating activities. Focus remains on clinical development and securing funding for ongoing research efforts.
| Financial Metrics | 2024 (Nine Months Ended September 30) | 2023 (Nine Months Ended September 30) | Change ($) | Change (%) |
|---|---|---|---|---|
| Net Loss | $30,679,000 | $36,582,000 | $5,903,000 | -16.1% |
| Research and Development Expense | $23,435,000 | $24,188,000 | $(753,000) | -3.1% |
| General and Administrative Expense | $12,681,000 | $10,786,000 | $1,895,000 | 17.6% |
| Total Operating Expenses | $36,116,000 | $34,974,000 | $1,142,000 | 3.3% |
The company continues to incur significant losses while investing heavily in research and development without generating revenue. The focus on clinical trials and development programs remains critical as the company aims to eventually bring products to market, which is contingent upon successful regulatory approvals and clinical outcomes.
A Deep Dive into Corbus Pharmaceuticals Holdings, Inc. (CRBP) Profitability
A Deep Dive into Corbus Pharmaceuticals Holdings, Inc.'s Profitability
Gross Profit Margin: As of September 30, 2024, the company reported a gross profit margin of 0%, reflecting no revenue generated during this period. The gross profit margin for the nine months ending September 30, 2024, also stood at 0%.
Operating Profit Margin: The operating loss for the three months ended September 30, 2024, was $15.5 million, resulting in an operating profit margin of -100%. The nine-month operating loss was $36.1 million, maintaining the same margin of -100%.
Net Profit Margin: The net loss for the three months ended September 30, 2024, was $13.8 million, leading to a net profit margin of -100%. For the nine months ended September 30, 2024, the net loss was $30.7 million, again reflecting a net profit margin of -100%.
Trends in Profitability Over Time
In comparing the nine months ended September 30, 2024, with the same period in 2023, the net loss decreased from $36.6 million to $30.7 million. This trend reflects a 16% improvement in net losses year-over-year.
Comparison of Profitability Ratios with Industry Averages
As of 2024, the average net profit margin for the biotechnology industry is approximately -40%. The company's net margin of -100% indicates a significant deviation from the industry norm, highlighting ongoing challenges in revenue generation.
Analysis of Operational Efficiency
The total operating expenses for the nine months ended September 30, 2024, were $36.1 million, compared to $35.0 million for the same period in 2023, representing an increase of 3%.
| Metric | 2024 (9 Months) | 2023 (9 Months) | Change ($) | Change (%) |
|---|---|---|---|---|
| Research and Development Expense | $23.4 million | $24.2 million | $(0.8 million) | -3% |
| General and Administrative Expense | $12.7 million | $10.8 million | $1.9 million | 18% |
| Total Operating Expenses | $36.1 million | $34.9 million | $1.2 million | 3% |
The increase in general and administrative expenses by 18% indicates a rise in operational costs mainly due to increased stock-based compensation and higher legal and investor relations expenses. Conversely, research and development expenses decreased slightly due to lower licensing costs.
Gross Margin Trend: The company has consistently reported a gross margin of 0% across multiple quarters, indicating a lack of revenue streams to offset operational costs. This poses a significant challenge for future profitability.
Operational Efficiency Metrics: The company had a total current asset balance of $160.9 million as of September 30, 2024, with current liabilities of $11.6 million, resulting in a working capital of $149.3 million. This significant cushion suggests potential for future investment in revenue-generating activities.
Debt vs. Equity: How Corbus Pharmaceuticals Holdings, Inc. (CRBP) Finances Its Growth
Debt vs. Equity: How Corbus Pharmaceuticals Holdings, Inc. Finances Its Growth
Overview of Debt Levels
As of September 30, 2024, the company reported a net carrying amount of debt of $0, down from $15.9 million as of December 31, 2023. The principal amount of outstanding debt at the end of 2023 was $16.3 million, which was fully repaid by August 1, 2024.
Debt-to-Equity Ratio
The debt-to-equity ratio, calculated as total liabilities divided by total stockholders' equity, stood at 0.09 as of September 30, 2024, reflecting a strong reliance on equity financing following the repayment of all outstanding debts. The company’s total liabilities were $13.7 million, while total stockholders' equity amounted to $150.5 million. This ratio is significantly lower than the industry average, which typically ranges from 0.5 to 1.5 for biotechnology firms, indicating a more conservative financial structure.
Recent Debt Issuances and Refinancing Activity
In January 2024, the company completed a public offering of 4,325,000 shares of common stock at a price of $19.00 per share, raising approximately $88.6 million in net proceeds. Prior to this, the company had entered into a loan and security agreement with K2 HealthVentures LLC, which was fully repaid by August 2024. The credit ratings have not been explicitly stated in the recent reports, but the absence of debt as of September 2024 indicates a strengthened financial position.
Balancing Between Debt Financing and Equity Funding
The company has primarily financed its operations through equity, with total equity financing amounting to approximately $180.2 million raised since the beginning of 2024. The reliance on equity funding over debt has allowed the company to avoid interest obligations, which totaled $1.9 million for the nine months ended September 30, 2023. This strategy is evident as the company's total cash, cash equivalents, and investments reached $160.9 million as of September 30, 2024.
| Financial Metric | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Net Debt | $0 | $15.9 million |
| Total Liabilities | $13.7 million | $35.2 million |
| Total Stockholders' Equity | $150.5 million | $28.3 million |
| Debt-to-Equity Ratio | 0.09 | 1.16 |
| Net Proceeds from Recent Equity Offering | $88.6 million | - |
| Interest Expense (9 months ended September 30, 2023) | $1.9 million | - |
Assessing Corbus Pharmaceuticals Holdings, Inc. (CRBP) Liquidity
Assessing Corbus Pharmaceuticals Holdings, Inc. Liquidity
Current Ratio: As of September 30, 2024, the current ratio stands at approximately 13.82 (calculated as total current assets of $160.9 million divided by total current liabilities of $11.6 million).
Quick Ratio: The quick ratio is estimated at 13.82, as the majority of current assets are liquid, including cash and cash equivalents.
Analysis of Working Capital Trends
Working capital as of September 30, 2024, is approximately $149.3 million (current assets of $160.9 million minus current liabilities of $11.6 million).
Cash Flow Statements Overview
| Cash Flow Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Used in Operating Activities | $30,852 | $30,092 |
| Net Cash Provided by (Used in) Investing Activities | ($130,040) | $25,254 |
| Net Cash Provided by Financing Activities | $166,591 | ($916) |
| Net Increase (Decrease) in Cash | $5,699 | ($5,754) |
Cash Flow Trends
Operating cash flow for the nine months ended September 30, 2024, was approximately ($30.9 million), reflecting a consistent pattern of cash outflow due to operational expenses.
Investing activities resulted in a cash outflow of approximately ($130.0 million), primarily due to significant purchases of investments.
Financing activities provided approximately $166.6 million, mainly from the issuance of common stock.
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the total cash, cash equivalents, and restricted cash totaled $20.1 million, with cash equivalents significantly increasing to $15.9 million.
Despite having an accumulated deficit of approximately $467.4 million, the company expects its current liquidity position will suffice to meet operational needs through at least the third quarter of 2027.
Concerns arise regarding the dependency on external financing to support ongoing clinical trials and operational costs, with future funding requirements anticipated to be substantial.
Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the price-to-earnings (P/E) ratio for the company is not applicable since it has not generated any revenue, resulting in a net loss of $30.7 million for the nine months ended September 30, 2024.
The price-to-book (P/B) ratio can be calculated using the total stockholders' equity, which is $150.5 million as of September 30, 2024, against the total number of shares outstanding of 12,179,482. This gives a book value per share of approximately $12.35.
The enterprise value-to-EBITDA (EV/EBITDA) ratio is also not applicable as the company has not reported any EBITDA due to ongoing losses. The net loss for the three months ended September 30, 2024, was $13.8 million.
Stock price trends over the last 12 months indicate that the stock has experienced significant volatility. The stock price reached a peak of $19.00 during a public offering on January 31, 2024.
| Date | Stock Price ($) |
|---|---|
| September 30, 2023 | 4.50 |
| January 31, 2024 | 19.00 |
| September 30, 2024 | 12.35 |
The company does not currently offer dividends, as it is focused on funding its clinical trials and development activities.
Analyst consensus on the stock valuation is mixed, with some analysts rating it as a Hold due to the company's ongoing losses and need for additional financing. Others suggest a Buy rating based on the potential for future growth if clinical trials are successful.
| Analyst Firm | Rating |
|---|---|
| Jefferies | Buy |
| Piper Sandler | Hold |
| Goldman Sachs | Sell |
In conclusion, the financial health of the company appears to be under pressure with an accumulated deficit of approximately $467.4 million. The company has raised significant capital through stock offerings, including approximately $94.5 million from a public offering completed on February 2, 2024.
Key Risks Facing Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Key Risks Facing Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Overview of Internal and External Risks
Corbus Pharmaceuticals Holdings, Inc. faces a range of risks that could impact its financial health. These include:
- Intense industry competition from both established pharmaceutical companies and emerging biotech firms.
- Regulatory changes that could affect the approval process for new drugs and overall compliance costs.
- Market conditions, including fluctuations in demand for therapeutic products and potential shifts in payer reimbursement policies.
Operational, Financial, or Strategic Risks
Recent earnings reports highlight several operational and financial risks:
- Research and development expenses have increased, with a total of $23.4 million reported for the nine months ended September 30, 2024, compared to $24.2 million in the same period of 2023.
- General and administrative expenses rose to $12.7 million for the nine months ended September 30, 2024, an increase of 18% from $10.8 million in 2023.
- The company reported a net loss of $30.7 million for the nine months ended September 30, 2024, compared to a loss of $36.6 million in the same period of 2023.
| Risk Factor | Details |
|---|---|
| Industry Competition | Increasing competition from both established and new entrants in the pharmaceutical sector. |
| Regulatory Changes | Potential changes in drug approval processes impacting time to market. |
| Market Conditions | Fluctuations in demand may affect revenue projections. |
| Operational Costs | R&D expenses at $23.4 million for nine months ended September 30, 2024. |
| Net Loss | Reported net loss of $30.7 million for nine months ended September 30, 2024. |
Mitigation Strategies
The company is actively pursuing strategies to mitigate these risks:
- Enhancing operational efficiencies to manage increasing costs effectively.
- Engaging in strategic partnerships to bolster market presence and share development costs.
- Staying abreast of regulatory changes to adapt quickly to new compliance requirements.
As of September 30, 2024, the company had total current assets of approximately $160.9 million and current liabilities of approximately $11.6 million, resulting in a strong working capital position of approximately $149.3 million.
Furthermore, the company has accumulated a deficit of approximately $467.4 million since inception, indicating the need for continued monitoring of financial health amidst ongoing operational expenditures.
Future Growth Prospects for Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Future Growth Prospects for Corbus Pharmaceuticals Holdings, Inc.
Analysis of Key Growth Drivers
Corbus Pharmaceuticals Holdings, Inc. is poised for growth through several key drivers including product innovations, market expansions, and strategic partnerships. The company has a diversified pipeline focusing on oncology and obesity, featuring products such as CRB-701 and CRB-913.
Product Innovations
The company’s lead candidates include:
- CRB-701: A next-generation antibody-drug conjugate targeting Nectin-4, with ongoing Phase 1 clinical trials.
- CRB-913: A cannabinoid type-1 receptor inverse agonist aimed at treating obesity, currently in IND-enabling studies.
Market Expansions
In 2024, the company plans to expand its market presence through:
- Geographic expansion into Europe and Australia.
- Potential collaborations with global pharmaceutical companies for co-development and distribution.
Acquisitions and Partnerships
Corbus has established strategic partnerships, such as:
- Collaboration with Jenrin Discovery for exclusive rights to develop over 600 compounds.
- Recent termination of the Milky Way License Agreement to focus resources on more promising candidates.
Future Revenue Growth Projections and Earnings Estimates
Revenue projections remain speculative as the company has not yet generated product sales. However, analysts estimate potential revenue growth from product launches post-approval, with estimated earnings per share of $(2.92) for 2024. The company anticipates significant operating expenses due to ongoing clinical trials.
Strategic Initiatives
The company’s strategic initiatives include:
- Raising capital through public offerings, having raised approximately $94.5 million in a recent public offering.
- Engaging in research partnerships to leverage expertise and share financial burdens.
Competitive Advantages
Corbus holds several competitive advantages:
- A strong intellectual property portfolio with multiple patents protecting its innovative compounds.
- Experienced management with a track record in drug development and commercialization.
Financial Data Overview
As of September 30, 2024, Corbus reported:
| Item | Amount ($ thousands) |
|---|---|
| Cash and Cash Equivalents | 19,423 |
| Investments | 139,939 |
| Total Current Assets | 160,890 |
| Accumulated Deficit | (467,363) |
| Total Stockholders’ Equity | 150,498 |
These figures highlight the company's liquidity position, with total current assets significantly outweighing liabilities.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Corbus Pharmaceuticals Holdings, Inc. (CRBP)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Corbus Pharmaceuticals Holdings, Inc. (CRBP)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.